DIABNEXT LIMITED TAIWAN BRANCH (HONG KONG)
Update:2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Integrating smartphones, cloud services, and wearable devices, it helps individuals with prediabetes and diabetes effectively manage their health.
The content above was translated by Ai
Founded Year
2013
Unified Business No.
54374223
Status
Closed
Number of Employees
0
Total capital
5,000,000 (NT$)
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
DIABNEXT LIMITED TAIWAN BRANCH (HONG KONG) was created around the idea of bringing large-scale and highly innovative solutions to improve the daily life of diabetes patients and help them better live with their disease. The DIABNEXT LIMITED TAIWAN BRANCH (HONG KONG) team has developed a patented solution innovative and unique compared to the existing monitoring solutions. While the market has focused on mobile apps requiring patients to enter their data by hand, DIABNEXT LIMITED TAIWAN BRANCH (HONG KONG) offers a unique solution combining hardware and software to automate the entry in the self-monitoring logbook. Based on several patents, DIABNEXT LIMITED TAIWAN BRANCH (HONG KONG) offers a complete solution for monitoring and therapeutic education “doing nothing more” than the actions directly associated with treatment: blood glucose level and insulin injection. The data is accessible to both patients and healthcare professionals who follow them.
The content above was translated by Ai